Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease

Kidney International

Volumn 84, Issue 6, 2013, Pages 1278-1286

  Boertien, Wendy E ^a   Meijer, Esther ^a   De Jong, Paul E ^a   Bakker, Stephan J L ^a   Czerwiec, Frank S ^b   Struck, Joachim ^c   Oberdhan, Dorothee ^b   Shoaf, Susan E ^b   Krasa, Holly B ^b   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Otsuka Pharmaceutical Development and Commercialization   (United States)

^c THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

ADPKD; clinical trial; glomerular filtration rate; renal hemodynamics; tolerance; vasopressin

Indexed keywords

TOLVAPTAN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY POLYCYSTIC DISEASE; MALE; MORNING DOSAGE; NOCTURIA; PLASMA OSMOLALITY; POLYURIA; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; URINE VOLUME; WEIGHT CHANGE; XEROSTOMIA;

ADULT; BENZAZEPINES; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HORMONE ANTAGONISTS; HUMANS; KIDNEY; MALE; MIDDLE AGED; NETHERLANDS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RECEPTORS, VASOPRESSIN; RENAL INSUFFICIENCY, CHRONIC; RENAL PLASMA FLOW, EFFECTIVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888646403     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.285     Document Type: Article

References (34)

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301.
2. Belibi FA, Reif G, Wallace DP et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004; 66: 964-973.
3. Grantham JJ. Lillian Jean Kaplan international prize for advancement in the understanding of polycystic kidney disease. understanding polycystic kidney disease: A systems biology approach. Kidney Int 2003; 64: 1157-1162.
4. Reif GA, Yamaguchi T, Nivens E et al. Tolvaptan inhibits ERK-dependent cell proliferation, cl secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 2011; 301: F1005-F1013.
5. Higashihara E, Torres VE, Chapman AB et al. Tolvaptan in autosomal dominant polycystic kidney disease: Three years' experience. Clin J Am Soc Nephrol 2011; 6: 2499-2507.
6. Wang X, Gattone V 2nd, Harris PC et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16: 846-851.
7. Torres VE, Wang X, Qian Q et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363-364.
8. Meijer E, Gansevoort RT, de Jong PE et al. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: Optimal timing and dosing of the drug. Nephrol Dial Transplant 2011; 26: 2445-2453.
9. Gattone VH 2nd, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323-1326.
10. Yamamura Y, Nakamura S, Itoh S et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-867.
11. Irazabal MV, Torres VE, Hogan MC et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011; 80: 295-301.
12. Torres VE, Meijer E, Bae KT et al. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study. Am J Kidney Dis 2011; 57: 692-699.
13. Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-2418.
14. Morgenthaler NG, Struck J, Alonso C et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112-119.
15. Morgenthaler NG, Struck J, Jochberger S et al. Copeptin: Clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43-49.
16. Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol Renal Physiol 1989; 256: F274-F278.
17. Yamada K, Nakano H, Nishimura M et al. Effect of AVP V1-receptor antagonist on urinary albumin excretion and renal hemodynamics in NIDDM nephropathy: Role of AVP V1-receptor. J Diab Comp 1995; 9: 326-329.
18. Aoyagi T, Izumi Y, Hiroyama M et al. Vasopressin regulates the reninangiotensin-Aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol 2008; 295: F100-F107.
19. Gellai M, Silverstein JH, Hwang JC et al. Influence of vasopressin on renal hemodynamics in conscious Brattleboro rats. Am J Physiol Renal Physiol 1984; 246: F819-F827.
20. Bouby N, Ahloulay M, Nsegbe E et al. Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 1996; 7: 842-851.
21. Schor N, Ichikawa I, Brenner BM. Mechanisms of action of various hormones and vasoactive substances on glomerular ultrafiltration in the rat. Kidney Int 1981; 20: 442-451.
22. Boberg U, Persson AE. Tubuloglomerular feedback during elevated renal venous pressure. Am J Physiol 1985; 249: F521-F531.
23. Ruggenenti P, Gaspari F, Cannata A et al. Measuring and estimating GFR and treatment effect in ADPKD patients: Results and implications of a longitudinal cohort study. PLoS One 2012; 7: E32533.
24. Shoaf SE, Bricmont P, Mallikaarjun S. Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects. Int J Clin Pharmacol Ther 2012; 50: 150-156.
25. Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br J Clin Pharmacol 2012; 73: 579-587.
26. Shoaf SE, Wang Z, Bricmont P et al. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 2007; 47: 1498-1507.
27. Ravine D, Gibson RN, Walker RG et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343: 824-827.
28. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470.
29. Boertien WE, Meijer E, de Jong PE et al. Short-term effects on efficacy parameters with tolvaptan in subjects with ADPKD at various levels of kidney function. In progress. 30. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.
30. Apperloo AJ, de Zeeuw D, Donker AJ et al. Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran. J Am Soc Nephrol 1996; 7: 567-572.
31. Donker AJ, van der Hem GK, Sluiter WJ et al. A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. Neth J Med 1977; 20: 97-103.
32. Michels WM, Grootendorst DC, Rozemeijer K et al. Glomerular filtration rate measurements by 125I-iothalamate should be corrected for inaccurate urine collections with 131I-hippuran. Clin Nephrol 2009; 72: 337-343.
33. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
34. Inker LA, Schmid CH, Tighiouart H et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-29.